News | June 26, 2026
Eli Lilly seals Centessa acquisition as it bets big on next-gen sleep disorder drugs
Centessa is a clinical-stage biotech focused on developing orexin receptor 2 agonists
Centessa is a clinical-stage biotech focused on developing orexin receptor 2 agonists
Bolstering neuroscience push with late-stage Tourette therapy
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
